Treatment with ethoxysanguinarine (a CIP2A inhibitor) reduced CIP2A expression in a 2,3-butanedione-induced rat model of bronchiolitis obliterans, which coincided with reduced EMT [4]. This evidence concerns the gene CIP2A and bronchiolitis obliterans syndrome.